J&J Closes the Loop with Animas Acquisition

Johnson & Johnson, whose LifeScan Inc. division is number one in the $6 billion glucose monitoring industry, acquired Animas, which after Medtronic MiniMed, is the number two player in the insulin pump market. J&J gets not only a leading insulin pump business, but also technology that lends itself to the future goals of all diabetes companies; the development of an artificial pancreas, or at least, the ability to automatically deliver insulin in response to automated continuous blood glucose measurements.

Johnson & Johnson , whose LifeScan Inc. division is number one in the $6 billion glucose monitoring industry, acquired Animas Corp. , which after Medtronic Inc. 's Medtronic MiniMed , is the number two player in the insulin pump market. [See Deal] Animas, a public company since 2004, [See Deal] will become a standalone entity reporting through LifeScan, and president Katherine Crothall, PhD will remain president of the division.

Under the terms of the transaction, which was approved by the boards of directors of both companies, J&J is paying...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.